Presentation of new GelX® data at the forthcoming CPHi Worldwide Congress, 25th October 2017.

July 10th 2017 Milan, Italy: BMG Pharma S.r.l., an innovative specialty pharmaceutical company, announces it will be presenting significant newly generated efficacy data on its GelX® product for the treatment of oral mucositis at the forthcoming CPHi Worldwide event in Frankfurt, October 2017.

Marco Mastrodonato, CEO of BMG Pharma S.r.l. commented– “This new data is a significant milestone for the company and which will allow GelX® to be available to a wider range of patients suffering from the side-effects of cancer treatment. The data will be showcased at a special presentation event’’

About  BMG Pharma S.r.l.

BMG Pharma S.r.l. is a specialty pharmaceutical company with its head office in Milan, Italy, leveraging its proprietary technology to develop products that address unmet needs of patients. The Company is currently focused on cancer supportive care, dermatology gynecology, ENT and oral health.  BMG Pharma S.r.l. is dedicated to helping patients, pharmacists and physicians by providing valuable and innovative products to the market.

The Company’s core areas are:

  • Presence in a number of important and growing therapeutic areas.
  • Specific & differentiated regulatory strategies for each product as Prescription and OTC Medical Devices in EC and US to allow rapid market introduction.
  • Bringing innovative products to market quickly with supportive clinical data.
  • IP protection for most products and technologies.
  • Full involvement in business collaboration and partnering.

For press releases and other company information, visit :
and contact :  Mrs. Loredana Galli,

BMG Pharma s.r.l

Via Confalonieri 29

20124 Milano, Italy

Telephone number: +39 02 91321756